InsidersTradesSigma
Veracyte, INC. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Veracyte, INC. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Veracyte, INC. has logged 261 insider filings. Market capitalisation: €4.6bn. The latest transaction was reported on 22 June 2026 (Cession). Among the most active insiders: McGuire Annie. All data is openly available.
261
Insider Decl.
0
Thresholds
€1m
3 ops.
Buy Volume
€13m
62 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Veracyte, INC. Buy (bullish), based on 10 analysts. Average price target: US$50.60.
51Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 12,443 of 25,898 companies
53.0
score / 100
Value33
Quality73
FCF yld2.8%
Earn yld1.5%
EV/EBITDA50.4x
ROE6.9%
Gross mgn70%
Net mgn13%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 June 2026
Declarations261 total
3,200 sharesCommon StockSEC:0001231845-26-000006:0
529 sharesCommon StockSEC:0001231845-26-000006:1
5,272 sharesCommon StockSEC:0001940521-26-000002:0
5,272 sharesCommon StockSEC:0001846905-26-000002:0
5,272 sharesCommon StockSEC:0001231845-26-000004:0
5,272 sharesCommon StockSEC:0001252004-26-000004:0
3,693 shares@ US$47.800.0034% mcap9.4% of flowCommon StockSEC:0001823563-26-000014:0
1,600 shares@ US$49.28360.0015% mcap4.2% of flowCommon StockSEC:0001823563-26-000014:1
1,961 shares@ US$50.09130.0019% mcap5.2% of flowCommon StockSEC:0001823563-26-000014:2
3,730 shares@ US$47.800.0034% mcap12.2% of flowCommon StockSEC:0001649245-26-000007:0
10,000 shares@ US$44.01290.011% mcap48.3% of flowCommon StockSEC:0001252004-26-000002:0
5,102 shares@ US$38.050.0047% mcap11.1% of flowCommon StockSEC:0001914620-26-000010
5,102 shares@ US$38.050.0054% mcap11.1% of flowCommon StockSEC:0001914620-26-000010:0
10,639 shares@ US$43.127726.3% of flowCommon StockSEC:0001914620-25-000012
10,639 shares@ US$43.12770.013% mcap26.3% of flowCommon StockSEC:0001914620-25-000012:0
3,052 shares@ US$46.168.2% of flowCommon StockSEC:0001914620-25-000010
7,914 shares@ US$46.1615.6% of flowCommon StockSEC:0001539796-25-000005
2,900 shares@ US$46.1630.2% of flowCommon StockSEC:0001991536-25-000008
3,052 shares@ US$46.160.0040% mcap8.2% of flowCommon StockSEC:0001914620-25-000010:0
7,914 shares@ US$46.160.010% mcap15.6% of flowCommon StockSEC:0001539796-25-000005:0
2,900 shares@ US$46.160.0038% mcap30.2% of flowCommon StockSEC:0001991536-25-000008:0
8,349 shares@ US$36.017450.0% of flowCommon StockSEC:0001649245-25-000005
8,349 shares@ US$36.01740.0084% mcap50.0% of flowCommon StockSEC:0001649245-25-000005:0
10,000 shares@ US$7.940.0022% mcap50.0% of flowCommon StockSEC:0001252004-25-000005:0
10,000 shares@ US$7.9450.0% of flowCommon StockSEC:0001252004-25-000005
25 of 261 declarations
About Veracyte, INC.
Veracyte, Inc. (NYSE/NASDAQ: VCYT) is a U.S.-listed precision diagnostics company headquartered in South San Francisco, California, with additional offices in San Diego, Austin, Texas, and Haifa, Israel. The company was built around a clear clinical mission: improve cancer care by providing molecular answers that help clinicians avoid unnecessary invasive procedures and get patients to the right treatment faster. Veracyte describes itself as a global diagnostics company focused primarily on oncology and certain interstitial lung diseases, with an international operational footprint and a growing evidence base supporting clinical adoption. ([veracyte.com](https://www.veracyte.com/company/)) Veracyte’s business model is centered on a diagnostics platform that combines genomic and clinical data, bioinformatics, artificial intelligence, and evidence generation. This platform approach is important because it supports test performance, reimbursement durability, and guideline adoption. The company’s core commercial products include Afirma, which is widely associated with thyroid nodule assessment, and the Decipher franchise, a genomic classifier used prominently in prostate cancer and broader urologic oncology applications. Veracyte also highlights emerging pipeline and platform initiatives, including TrueMRD and planned Prosigna LDT-related launches, indicating continued investment in expanding its addressable market across the cancer care continuum. ([investor.veracyte.com](https://investor.veracyte.com/)) From a competitive standpoint, Veracyte differentiates itself through a high-value diagnostic niche: helping physicians make more confident decisions while reducing unnecessary procedures and associated costs. Rather than competing as a broad-based in vitro diagnostics vendor, the company has positioned itself as a leader in evidence-backed oncology diagnostics, where clinical utility, reimbursement, and physician trust are key barriers to entry. Management has also emphasized that growth is being driven primarily by Decipher and Afirma, underlining the importance of these franchises to the investment case. ([investor.veracyte.com](https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-fourth-quarter-and-full-year-2025-financial)) Recent developments have reinforced the growth narrative. In November 2025, Veracyte reported strong testing-revenue momentum and highlighted a Cell publication from the STAMPEDE trial showing that Decipher Prostate can predict chemotherapy benefit in metastatic prostate cancer, while also launching the Afirma v2 transcriptome to improve operational efficiency and serve as a platform for future products. In February 2026, the company reported full-year 2025 results, with strong double-digit growth in both Decipher and Afirma and more than 45,000 patients served with its core testing business in the quarter. These updates suggest a business that is scaling well while investing in its next wave of diagnostic innovation. ([investor.veracyte.com](https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-third-quarter-2025-financial-results))
